SCHEMBL7014701

SCHEMBL7014701

c1ccc(Oc2ccc(-c3ncccn3)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 2/20 0.61
LTA4H P09960 7/20 0.55
TSHR P16473 1/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
SCN4A P35499 1/20 0.52
RIPK1 Q13546 1/20 0.50
NISCH Q9Y2I1 1/20 0.49
GSTP1 P09211 1/20 0.48
NR1H2 P55055 1/20 0.46
BAX Q07812 1/20 0.46
MAOA P21397 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TLR8 Q9NR97 1/20 0.46
DYRK1A Q13627 1/20 0.46
ADRB2 P07550 1/20 0.45
MAPK14 Q16539 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21882442 0.90 CLK4 (0.55) CLK4LTA4HNPC1RAB9ASCN4A
SCHEMBL6326962 0.83 CLK4 (0.57) CLK4NPC1RAB9ASCN4AADRB2
SCHEMBL11485534 0.83 LTA4H (0.48) CLK4LTA4HTSHRNPC1RAB9A
SCHEMBL6741053 0.83 KMT2A (0.61) LTA4HNPC1RAB9AALDH1A1
SCHEMBL8440332 0.80 NPC1 (0.55) LTA4HTSHRNPC1RAB9ASCN4A
SCHEMBL21887691 0.80 MAPK1 (0.58) LTA4HTSHRNPC1RAB9ASCN4A
SCHEMBL30681806 0.80 LTA4H (0.49) LTA4HNPC1RAB9ASCN4ARIPK1
SCHEMBL2194874 0.79 CYP1A2 (0.59) LTA4HTSHRNPC1RAB9ASCN4A
SCHEMBL3157659 0.79 RAB9A (0.64) CLK4TSHRNPC1RAB9AALDH1A1
SCHEMBL6406035 0.78 LTA4H (0.75) LTA4HTSHRNPC1RAB9ASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104341388-B Aromatic amide derivative as well as preparation method and medicinal application thereof 北京诺诚健华医药科技有限公司 2017-03-22 CN disclosed
CN-103814016-B Compositions and methods for producing pyrimidine and pyridine compounds having BTK inhibitory activity 默克专利有限公司 2017-03-08 CN disclosed
US-20140323501-A1 AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2014-10-30 US disclosed
US-20140323501-A1 AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2014-10-30 US disclosed
US-20140323501-A1 AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2014-10-30 US disclosed
EP-2786982-A1 AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2014-10-08 EP disclosed
EP-2786982-A1 AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2014-10-08 EP disclosed
WO-2013004190-A1 AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国医学科学院药物研究所 (CN) 2013-01-10 WO disclosed
CN-1147492-C New metal protease inhibitors, its preparing method and their medicinal composition containing them ɪά��ʵ���� 2004-04-28 CN disclosed
EP-1065209-B1 Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-05-02 EP disclosed
US-6339092-B1 FOR THERAPY RHEUMATOID ARTHRITIS, ARTHROSIS, TUMOUR INVASION AND GROWTH, INCLUDING MALIGNANT SPREAD AND THE FORMATION OF METASTASES, ULCERATIONS, ATHEROSCLEROSIS ADIR ET COMPAGNIE (FR) 2002-01-15 US disclosed
EP-1065209-A1 Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323501-A1 AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF AADAT, HPGDS, HLA-DRB1 CLK4 4028/4885LTA4H 601/4885TSHR 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.